youtube_live
Q2 2027 earnings • in 4 days
See detailschevron_right
DRREDDY:NSE
Dr Reddy's Laboratories Ltd
₹1,242.50
arrow_upward
+0.77%(+9.50) 1D
Oct 19, 3:30:00 PM GMT+5:30 · INR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DRREDDY...
Open
₹1,232.00
High
₹1,245.00
Low
₹1,227.00
Mkt. cap
1.03T
Avg. vol.
1.92M
Volume
1.02M
Dividend
0.64%
Quarterly dividend
₹2.00
Ex-dividend date
Jul 10, 2026
P/E ratio
32.13
52-wk high
₹1,414.90
52-wk low
₹1,101.00
EPS
₹38.67
Shares outstanding
166.06M
No. of employees
28K
Open
₹1,232.00
High
₹1,245.00
Low
₹1,227.00
Mkt. cap
1.03T
Avg. vol.
1.92M
Volume
1.02M
Dividend
0.64%
Quarterly dividend
₹2.00
Ex-dividend date
Jul 10, 2026
P/E ratio
32.13
52-wk high
₹1,414.90
52-wk low
₹1,101.00
EPS
₹38.67
Shares outstanding
166.06M
No. of employees
28K
News stories
From web sources and news partners
TradingView
·
1 hour ago
Broader S&P 500 set to outpace Mag 7 in earnings growth for first time since 2022
The Motley Fool
·
9 minutes ago
3 Unstoppable Dow Stocks to Buy Before October Ends
The Lufkin Daily News
·
1 hour ago
Nasdaq climbs as chip and AI-linked stocks bounce back
KuCoin
·
1 hour ago
The Dow finished last week up 0.7%. Most of the stock market
Profile
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad, with U.S. headquarters in East Brunswick, New Jersey. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy's manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
About Dr Reddy's Laboratories Ltd
CEOErez Israeli
Employees27.5K
Founded1984
HeadquartersHyderabad, Andhra Pradesh, India
SectorPharmaceutical industry
Websitedrreddys.com